Researchers at the Francis Crick Institute have mapped all the possible outcomes of changes to a tumor-suppressing gene called VHL, the first step in a huge research endeavor to unpick the outcomes of ...
ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results Patients diagnosed with hereditary RC are more prone to ...
More than half of patients with VHL-associated RCC in a phase 2 trial remained on belzutifan treatment, with no new safety signals. Belzutifan, a hypoxia-inducible factor-2α inhibitor, durably shrinks ...
Researchers have mapped all the possible outcomes of changes to a tumor-suppressing gene called VHL, the first step in a huge research endeavor to unpick the outcomes of tens of thousands of genetic ...
uring the 1990s, several labs in the United States and United Kingdom investigated the von Hippel-Lindau tumor suppressor (pVHL). Many important findings developed, including the belief that HIF ...
Institute of Cancer Research UK has identified proteolysis targeting chimeras (PROTACs) comprising a Von Hippel-Lindau disease tumor suppressor (VHL) binding moiety coupled to a receptor-interacting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback